TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

TScan Therapeutics, Inc.NASDAQ: TCRX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $2.47M fell 27.8% year over year, behind the -2.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +37.0% a year.

Context

  • Stock-based compensation amounted to 113.4% of revenue in FY2025, down 225.7 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -27.8% toward the trailing-twelve-month pace of -2.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.47M+22.8% QoQ
Last fiscal yearDec 2025
$11.71M+22.6% YoY
LTMMar 2026
$10.76M-2.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.8%——
1 year+22.6%——
3-year CAGR+37.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.71M USD
Year-over-year change
+22.6%
4-year CAGR
+46.9%

Stock-Based Compensation vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's LTM Mar 2026 stock-based compensation of $10.76M is the 6th largest of the 10 companies compared; the peer median is $11.29M.
  • Its year-over-year change of -2.0% is the 3rd highest of 10, against a peer median of -25.5%.
  • Stock-based compensation amounts to 117.7% of revenue for TCRX, versus a peer median of 33.9%.
TCRX Competitors Peer median
Stock-Based Compensation for TCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$22.45M -34.1%+7.7%33.9%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$13.93M -47.2%-30.3%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$13.11M -11.0%+88.9%—
ACETAdicet Bio, Inc.LTM Mar 2026$12.39M -37.2%-5.9%—
IMUXImmunic, Inc.LTM Mar 2026$11.29M +44.4%+3.8%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$10.76M -2.0%+37.0%117.7%
VXRTVaxart, Inc.LTM Mar 2026$7.34M -25.5%-15.1%2.9%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$5.81M -25.3%-16.6%—
NTRBNutriband Inc.LTM Apr 2026$3.23M +3574.0%-47.8%179.0%
XBITXBiotech Inc.LTM Mar 2026$465K -90.1%-10.6%—
Peer median (excluding TCRX) $11.29M-25.5%-10.6%33.9%

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
Deferred Income Tax(9.16M)0000
Stock-Based Compensation2.52M4.55M5.21M9.55M11.71M
Change in Working Capital(5.9M)(10.23M)17.61M5.05M(18.18M)
Accounts Receivables00000
Inventory00000
Accounts Payables10K528K(52K)1.99M(3.01M)
Other Working Capital(5.91M)(10.76M)17.66M3.06M(15.17M)
Other Non-Cash Items9.16M260K(315K)(2.03M)(1.95M)
Operating Cash Flow(48.68M)(66.5M)(61.36M)(110.82M)(135.32M)
Capital Expenditures(9.94M)(4.23M)(3.15M)(3.83M)(4.41M)
Acquisitions (Net)00000
Purchases of Investments00(77.61M)(241.45M)(87.47M)
Sales of Investments0020M192.66M201.25M
Other Investing Activities00000
Investing Cash Flow(9.94M)(4.23M)(60.76M)(52.61M)109.37M
Debt Repayment029.35M015.31M0
Common Stock Issued89.65M193K42.41M33.13M264K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities291K(191K)93.03M160.32M(600K)
Financing Cash Flow189.67M29.36M135.44M208.77M(336K)
Effect of Forex Changes00000
Net Change in Cash131.05M(41.37M)13.33M45.33M(26.28M)
Free Cash Flow(58.62M)(70.73M)(64.5M)(114.65M)(139.73M)

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.